title: Long-term follow-up of allogeneic bone marrow transplantation for patients with chronic phase chronic myeloid leukemia prepared with a regimen consisting of cyclophosphamide, cytarabine and single-dose total body irradiation conditioning.
abstract: We evaluated long-term toxicities and outcomes in 96 patients with chronic phase chronic myeloid leukemia treated with a single bone marrow allograft regimen. Conditioning was cytosine arabinoside, cyclophosphamide (120 mg/kg) and single fraction total body irradiation (500 cGy). Median follow-up was 12.8 years (0.4-19.9 years). Graft failure occurred in one patient, nonfatal veno-occlusive disease in 13 patients (14%). Overall incidences of acute (a) and chronic (c) graft-vs-host disease (GVHD) were 77 and 63%. The 100-day and 1-year transplant-related mortality (TRM) were 1 and 9.2%, respectively, with no change through 5 years. Five- and 10-year event-free survival rates were 56 and 49%, overall survival (OS) rates 72 and 70%, respectively. Forty patients have relapsed: 8 cytogenetic (20%), 10 hematologic (25%) and 22 molecular (55%). Most have been salvaged with donor-leukocyte infusion, second transplants and/or imatinib therapy. Survival was worse for patients transplanted >2 years from diagnosis (10-year OS 56 vs 78%, P=0.01), for patients over 50 years old (10-year OS 44 vs 75%, P=0.05) and for patients without cGVHD (10-year OS 53 vs 86%, P<0.001). This regimen resulted in successful engraftment, low risk of TRM and long-term survival. In an era when imatinib is first line therapy, this regimen offers a potentially low-toxicity, highly successful alternative in the event of poor imatinib response.
authors.affiliation: Department of Medical Oncology and Hematology, University of Toronto Allogeneic Blood and Marrow Transplant Program, Toronto, Ontario, Canada.
authors.forename: Y
authors.initials: Y
authors.lastname: Zaretsky
authors.forename: J
authors.initials: J
authors.lastname: Rifkind
authors.forename: G
authors.initials: G
authors.lastname: Lockwood
authors.forename: R
authors.initials: R
authors.lastname: Tsang
authors.forename: T
authors.initials: T
authors.lastname: Kiss
authors.forename: W
authors.initials: W
authors.lastname: Hasegawa
authors.forename: G
authors.initials: G
authors.lastname: Fyles
authors.forename: I
authors.initials: I
authors.lastname: Tejpar
authors.forename: D
authors.initials: D
authors.lastname: Loach
authors.forename: M
authors.initials: M
authors.lastname: Minden
authors.forename: H
authors.initials: H
authors.lastname: Messner
authors.forename: J H
authors.initials: JH
authors.lastname: Lipton
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease; D006801:Humans; D015466:Leukemia, Myeloid, Chronic-Phase / Q000150:complications / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D016879:Salvage Therapy / Q000379:methods; D016019:Survival Analysis; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods*; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014916:Whole-Body Irradiation / Q000379:methods
chemical_list: D003561:Cytarabine; D003520:Cyclophosphamide